Continued Treatment of Early Nonresponders or Partial Virologic Responders with Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses

Category Primary study
JournalGut and liver
Year 2023
Background/Aims Bulevirtide (BLV) is a novel entry inhibitor of hepatitis delta virus (HDV). In clinical studies, virologic responders (VR) to HDV therapy are defined as patients who achieve a ≥2log10 IU/mL decline in HDV RNA from baseline (BL) or undetectable level (50% from baseline in 5 of 6 NR (1 achieved ALT WNL). Many patients who were PR (18 of 24; 75%) or NR (6 of 14; 43%) to BLV at W24 achieved VR by W96, with ALT improvements evident in all groups, including NR. Conclusion These results provide evidence for continuing BLV therapy despite early suboptimal virologic responses in CHD patients. (Table Presented).
Epistemonikos ID: 79f05b90a4532af2b8a157383d49fa0c60e33278
First added on: Apr 29, 2024